Surprisingly, the patient truly showed such a high-volume, invasive prostate cancer with extensive disease burden but disproportionately low PSA level, which adds diagnostic complexity and challenges to contemporary prostate cancer management (19). This evidence concerns the gene KLK3 and prostate carcinoma.